MCI & Alzheimer’s Disease Trials in Blackpool – Biotrax Clinical Trials, Medical Trials, Drug Trials, Medical Research and Clinical Research

MCI & Alzheimer’s Disease Trials in Blackpool



MAC CLINICAL RESEARCH
  • Post Date: August 29, 2018
  • Applications 0
  • Views 63
Job Overview








Alzheimer’s Clinical Trial

Study Name: MCI and ALZHEIMER’S DISEASE



Clinics: Blackpool

Therapy Area: MCI and Alzheimer’s disease

Gender and Age: Male and Female ages 50 – 85

Description:

Alzheimer’s Disease is the main form of dementia and it is estimated that the condition affects around 40 million people worldwide, mostly older than 60 years. There’s a critical unmet need for medication that can combat the progression of the disease. Currently, there’s only a handful of medications available on prescription in the UK to help combat AD. This investigational drug, only known at present as Elenbecestat (E2609), has been designed to ‘block’ the build-up of the beta-amyloid in the brain, in theory slowing down the progression of the disease. This current trial is 29 months long with 16 visits to the Blackpool clinic over that time. There’s a 1:1 placebo ratio with the investigational drug and it is to be taken orally, once a day, with or without food.

Please contact MAC for more information.

Reimbursement: We will reimburse reasonable travel expenses or provide transport and provide meals where necessary.

Criteria:

Key Inclusion Criteria*

    ​Diagnosis of Mild Cognitive Impairment, Early Alzheimer’s Disease or history of cognitive decline in the past 12 months,

    MMSE >= 24

    Study partner

Key Exclusion Criteria*

    Other form of dementia​

    Unstable medical condition

    Contraindications to MRI scanning

Other eligibility criteria will apply. Please contact MAC for more information.

Any other information
Eligible patients will receive a comprehensive health screen and study participation will be in collaboration with the patient’s treating physician.

There also may be the opportunity to continue into an open label extension study where all participants will be receiving the active drug.



Job Detail
  • Gender RequiredBoth
  • Ethnic originEveryone Accepted
  • Age RangeAdult : 20 - 65 years
  • SmokerNo
  • Reimbursement OfferedReimbursement Offered
  • Participant Inclusion CriteriaDiagnosis of Mild Cognitive Impairment, Early Alzheimer’s Disease or history of cognitive decline in the past 12 months, MMSE >= 24 Study partner
  • Participant Exclusion CriteriaOther form of dementia​ Unstable medical condition Contraindications to MRI scanning
  • DurationNot given
Shortlist Never pay anyone for job application test or interview.